REPLIGEN CORP — Director's Dealing 2019

Jun 20, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2019-06-17

Reporting Person: DAWES KAREN A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-17	Common Stock	M	20000	$4.96	Acquired	118329	Direct
2019-06-17	Common Stock	S	1295	$77.35	Disposed	117034	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-17	Stock Options (Right to Buy)	$4.96	M	20000	Disposed	2019-09-11	Common Stock (20000)	Direct

Footnotes

F1: Sale of common stock to cover the exercise price and a portion of the tax liability resulting from the exercise of Ms. Dawes's stock options was allowed pursuant to an exception to a lock-up agreement, signed by Ms. Dawes on April 26, 2019 in connection with the public offering of the Company's common stock.

F2: $77.35 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.24 to $77.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: This option is currently exercisable.